The collaboration between Ariana Pharma, Omicure, and the Léon Bérard Center has led to a breakthrough in identifying survival biomarkers across various cancer types using eXplainable Artificial Intelligence. In a study, presented at ESMO 2023 [Identification of biomarkers of survival across multiple cancer types using eXplainable Artificial Intelligence], KEM®, a proprietary Ariana Pharma technology, was […]
Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological […]
Cambridge, MA, USA and Paris, France, March 27, 2023 – Ariana Pharma, the leading Al-driven precision medicine company, has announced the appointment of Professor Jacques Touchon to its Scientific Advisory Board.
• Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases
• CY6463 favorable tolerability and safety profile was confirmed
Blarcamesine significantly restores functionality in key molecular pathways including Alzheimer’s and Parkinson’s disease, KEM® xAI analysis shows. Cambridge, MA, USA and Paris, France, October 4th, 2022 – Ariana Pharma, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical […]
Paris, France and Cambridge, MA, USA, July 26th, 2022 – Ariana Pharma, the leading eXplainable Artificial Intelligence (xAI) drug development company, announce the appointments of Dr. Marion Soto as Vice President, Business Development and Bertrand Lellouche as Chief Financial Officer. The financial and commercial experience of Marion and Bertrand will further drive Ariana’s accelerated growth. […]
Paris and Cambridge, MA, June 15th 2022. Ariana Pharma and OmiCure announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Ariana Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were communicated at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have […]
Pushing the promise of AI designed Precision Medicine Parkinson’s Disease Dementia (PDD) therapy closer to the finish line, Ariana, the AI Drug Development Company and ANAVEX Life Sciences announced positive ANAVEX®2-73 Phase II results.
Collaboration to identify patient-selection biomarkers for Cyclerion’s investigational therapeutics in neurological and neuropsychiatric diseases associated with cognitive impairment
Prior to joining Ariana, Hichem was Director of Development Operations at Sanofi. Hichem’s significant achievements encompass multiple therapeutic areas